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Abstract
Objective: To evaluate the feasibility of continuous telemetric trans-abdominal fetal electrocardiogram (a-fECG) in women
undergoing labour induction at home.
Study Design: Low risk women with singleton term pregnancy undergoing labour induction with retrievable, slow-release
dinoprostone pessaries (n=70) were allowed home for up to 24 hours, while a-fECG and uterine activity were monitored in
hospital via wireless technology. Semi-structured diaries were analysed using a combined descriptive and interpretive
approach.
Results: 62/70 women (89%) had successful home monitoring; 8 women (11%) were recalled because of signal loss. Home
monitoring lasted between 2–22 hours (median 10 hours). Good quality signal was achieved most of the time (86%, SD
10%). 3 women were recalled back to hospital for suspicious a-fECG. In 2 cases suspicious a-fECG persisted, requiring
Caesarean section after recall to hospital. 48/51 women who returned the diary coped well (94%); 46/51 were satisfied with
home monitoring (90%).
Conclusions: Continuous telemetric trans-abdominal fetal ECG monitoring of ambulatory women undergoing labour
induction is feasible and acceptable to women.
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Introduction
The number of induced labours continues to increase with
emerging evidence that induction of labour at term does not
appear to increase caesarean delivery rates, but may benefit both
mother and baby [1–4].
Home induction has emerged as an increasingly popular
alternative to labour induction in hospital settings [5–6].
Unfortunately, safer alternatives to prostaglandins do not appear
to be effective [7–8], and concerns for the fetal wellbeing during
home inductions remain the key issue.
Induction of labour is also associated with decreased maternal
satisfaction when compared with spontaneous labour [9]. Key
negative influencing factors are the lack of comfort, privacy and
flexibility in a hospital environment. Outpatient induction has
been shown to increase maternal satisfaction; the home environ-
ment is private and familiar, thus increases control [10].
A home induction protocol that complements use of slow
release, retrievable prostaglandin pessary, with an user friendly
remote fetal monitoring system, may provide a solution to the
current concerns. Monica AN24 (Monica Healthcare Ltd) is a
commercially available, wireless fetal-maternal monitoring device
that allows remote non-invasive trans-abdominal monitoring of
fetal heart activity (electrocardiography, ECG), uterine electrical
activity (electromyography, EMG) and maternal heart rate in real-
time (Figure 1 & 2). Our aim was to explore whether such remote
continuous trans-abdominal fetal ECG monitoring in women
undergoing induction of labour with retrievable, slow release
prostaglandin pessary is feasible and acceptable to women.
Methods
Ethics Statement
This was a prospective cohort study carried out at Liverpool
Women’s Hospital Trust between January 2009 and December
2010, for which the Ethics Committee (Cheshire Research Ethics
Committee) approval was obtained (REC-08/H1017/194), and
Trust Research and Development approval reference (LWH0764).
Written informed consent was obtained from all the participants in
the study. The consent was given by the participants for their
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research by the responsible individuals.
There were 3 phases to this study:
i) In-patient phase
We recruited a total of 16 women in order to test the feasibility
of the telemetric a-fECG monitoring device. The signal was
transmitted through the a-fECG monitoring device to a standard
hospital monitor (PC), via ordinary cell phone (Bluetooth
technology) to an online data reception server, accessible to the
hospital staff through the internet. Simultaneous recordings of fetal
ECG, uterine electrical activity and maternal heart rate were
displayed with a delay of only 40 seconds.
All 16 women with singleton, cephalic pregnancies had their
labour induced with slow release retrievable 10 mg dinoprostone
pessary (Propess, Ferring Pharmaceuticals). The indications were:
post-term (n=8), gestational diabetes (n=1), polyhydramnios
(n=2), proteinuria (n=1), hypertension (n=1), severe symphysis
pubic dysfunction (n=1), asthma (n=1) and prolonged rupture of
membranes (n=1).
After obtaining written informed consent, the a-fECG moni-
toring device was attached. Concurrently, standard CTG Doppler
was positioned over the a-fECG monitoring device and 30 minutes
of simultaneous monitoring carried out. Fetal well-being was
further confirmed for 60 minutes after insertion of vaginal
dinoprostone. After this, standard CTG Doppler was removed
whilst monitoring continued only with a-fECG monitoring device
for a maximum of 24 hours or until delivery. Total duration for
fetal ECG monitoring ranged between 3 and 20 hours.
ii) Outpatient monitoring in healthy controls
In this phase, the a-fECG was used in 11 healthy pregnant
volunteers at term. They all had low risk singleton, cephalic
pregnancy. They were awaiting either spontaneous onset of labour
or post-term induction of labour. These women were monitored
whilst at home for up to 24 hours. Simultaneous recordings of fetal
ECG, uterine activity and maternal heart were checked remotely
for the signal quality. The duration of recordings ranged from 8 to
21 hours. The real time recordings could not be initiated despite
electrode adjustments in 3 out of 11 women. Adequate signals
were eventually achieved when devices were replaced. In one case
there was a significant loss of signal at home which prompted us to
amend the monitoring protocol. We included an option of
advising subsequent participants that they may be asked to lie
down for 30–60 minutes at home in order to reduce the signal loss
due to excess mobility.
The quality of signal was quantified as the percentage of
monitoring time during when it was possible to calculate the ‘‘two
seconds average’’. For each woman, the total a-fECG recording
was divided into 2 second epochs. Each epoch was checked for a
minimum of two consecutive fetal and maternal ECG complexes
which, if present, enabled a heart rate to be calculated for that
epoch. Success rate was expressed as a % of the number of epochs
Figure 1. Fetal ECG monitoring device (MONICA AN24).
Copyright and courtesy of Monica healthcare limited. Portable trans-
abdominal fetal ECG monitoring device with 5 electrodes attached to
the maternal abdomen.
doi:10.1371/journal.pone.0028129.g001
Figure 2. Monitoring display. Continuous monitoring display from the MONICA AN24 device of fetal and maternal heart rate, uterine contractions
and maternal movements. (Fetal heart rate – black line (top); maternal heart rate – green line (middle); Uterine contractions – black line (bottom);
maternal movements – orange bars).
doi:10.1371/journal.pone.0028129.g002
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the total number of epochs per hour.
We have pre-specified the targets for success rate based on the
low clinical risk status of participant and expected significant
mobility during day time i.e. .70% during day time and .80%
during night time. As the overall percentage of success rate
exceeded pre-specified criteria in 10 out of 11 participants, the
quality of the monitoring was judged to be of sufficient quality to
be tested for induction of labour at home.
We noted that one woman reported mild itching on the
abdomen after removal of the abdominal electrode.
iii) Home induction cohort
Women with healthy singleton pregnancy, cephalic presenta-
tion, gestational age $37
+0 weeks and parity ,4, who were
scheduled for induction of labour were provided with information
leaflets about the study and asked to sign a written consent. Only
women with intact membranes, Bishop score ,6; and normal
trans-abdominal fetal ECG monitoring for 60 minutes after
insertion of slow release retrievable dinoprostone pessary were
eligible for home induction. We excluded women who did not
have a birthing partner at home, did not have access to both
telephone and transport, or were living . 60 minutes drive from
hospital. Women with medical problems, previous caesarean
delivery, maternal age , 18 years and contra-indication to slow
release 10 mg dinoprostone pessary were also excluded.
All eligible women were sent home with 10 mg dinoprostone
pessary while being continuously monitored telemetrically with
trans-abdominal fetal ECG monitoring device.
Fetal ECG, uterine activity and maternal heart rate were
reviewed at least once every hour by the midwifery staff. Women
were advised to return to hospital if pessary fell out, in case of
vaginal bleeding or ruptured membranes, painful uterine contrac-
tions requiring analgesia, continuous abdominal pain, or contrac-
tions occurring at a frequency of $3 in 10 minutes or lasting .60
seconds (allowing hospital delivery for all women). Women were
also contacted in case of signal loss, trace concerns or transmission
failure and were asked to return to hospital if connection could not
be re-established.
If active phase of labour started within the battery life time (20–
24 hours), the trans-abdominal fetal ECG monitoring was
continued. Standard Doppler fetal heart rate (FHR) monitoring
was used instead when batteries were used up, or when access to
online data reception server was not available in the allocated
delivery suite room. Standard Doppler FHR monitoring was also
routinely used in the second stage of labour, because of the
possibility of losing a-fECG signal secondary to fetal descent.
iv) Qualitative assessment
Maternal views were assessed using semi-structured diaries. The
diaries recorded women’s ratings, on a 4 point scale, of how well
they were coping, their comfort and satisfaction with outpatient
experience. Additional free-text space allowed for comments on
any side effects, concerns and positive or negative aspects of the
care. Women were asked to complete diaries at least once every
two hours during their time at home and indicate their location
preference on each entry. Diaries were collected on admission to
hospital and forwarded to the qualitative team. Mean scores were
calculated for women’s ratings of coping, comfort, satisfaction and
location preference. An interpretive approach was utilised for all
open responses [11]. Comments made in the free-text spaces of
diaries were identified and summarised in order to contextualise
women’s ratings of their experience.
Results
104 women consented to participate, of whom 24 laboured
before the induction date. In addition, three women had Bishop
Score .6 on the day of induction and there was one case of a cord
presentation. Two women changed their mind and withdrew
consent. In four instances it was not possible to establish the link
between the a-fECG device and the online server (data reception
point) despite adequate a-fECG recordings.
In total, 70 women fulfilled all eligibility criteria and were sent
home with slow release dinoprostone pessary in situ (Table 1). Two
women required caesarean section with suspicious FHR trace
before active phase of labour was established (see below) and two
women had Caesarean section for failed induction.
i) Home monitoring
Out of 70 women who were sent home, 62 (89%) were
successfully monitored at home (Table 2). Three women (4%)
developed non-reassuring FHR (suspicious) at home. They were
instructed via telephone to remove dinoprostone pessary imme-
diately and return back to hospital. In two cases, FHR became
pathological requiring Caesarean section 2 and 4 hours later,
respectively. Both babies were born with normal Apgar scores and
normal arterial cord pH values of 7.37; BE 23 and 7.30; BE 2.3
respectively. In both cases no obvious cause for deteriorating a-
fECG was identified at the time of caesarean delivery. In the third
case a-fECG trace improved spontaneously to normal and
remained normal until normal vaginal birth, 8 hours after return
to hospital.
There were 2 cases of mild hyperstimulation at home. In both
cases the midwife reviewing the a-fECG trace, noticed five or
more contractions in 10 minutes lasting for over 30 minutes with
completely reassuring FHR trace. Both women were contacted at
home to inquire about the frequency and strength of contractions.
One of these women confirmed feeling 1–3 contractions every 10
minutes which were of variable strength, but wished to stay at
home as was coping quite well. Her trace was reviewed regularly
Table 1. Demographic and clinical characteristics of women
who were monitored at home (n=70).
Indication for induction
Post-term 69
Symphysis pubis dysfunction 1
Gestational age (days)
a 291 ( 2.5)
Body Mass Index (BMI) .35 6 (9%)
Nulliparous 45 (64%)
Bishop Score at start
b 3 (0–5)
Successful induction (Bishop $6 within 24 hours) 53 (76%)
Additional dinoprostone 13 (19%)
Caesarean section 14 (20%)
Pre-labour (suboptimal CTG) 2
Pre-labour (failed induction) 2
Intrapartum 10
Birth weight (grams)
a 3700 (396)
Apgar Score , 7 at 5 minutes
c 3( 4% )
aMean (standard deviation).
bMedian (range).
cCord pHs - normal for these 3 cases.
doi:10.1371/journal.pone.0028129.t001
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hyperstimulation. The second patient was already getting ready to
make her way to the hospital. She confirmed to have ruptured her
membranes at home and was feeling 4–6 painful uterine
contractions every 10 minutes in the previous hour and a half.
She arrived in hospital safely. Her first dinoprostone pessary had
fallen out when her membranes ruptured and her contractions
eased off completely within 3 hours of arrival. The decision was
made to put in a 2nd dinoprostone pessary which was removed
4 hours later because of hyperstimulation without FHR changes.
Terbutaline was given and vaginal delivery was achieved 4 hours
later. Her baby was born with Apgar score of 6 at 5 minutes, but
normal venous cord PH of 7.42 with BE of 24.4. Arterial cord
sample was inadequate to be processed.
There were further 2 cases where the Apgar scores were ,7a t5
minutes. Both of these women were in hospital during active phase
of labour. One baby had a rotational forceps delivery in theatre
(cord arterial PH of 7.16 & BE 27.8). The second was a normal
vaginal delivery after syntocinon infusion for 8 hours (cord arterial
pH of 7.27, BE 25.2).
All the remaining 55 women who were successfully monitored
at home delivered babies with Apgar scores of more than 7 at 5
minutes. Cord PH was successfully obtained in 43 of these 55
patients and there was no evidence of hypoxia or acidosis.
The duration of a-fECG monitoring at home ranged from
1 hour and 55 minutes to 22 hours and 4 minutes (median time 10
h 35 min). On average, the a-fECG was able to calculate and
display recordings successfully in 86% of total recording time per
woman (SD 10.5 %).
Prolonged signal transmission disruptions were encountered in 8
cases (11%) requiring recall to hospital for in-patient monitoring.
None of these women were in established labour; they returned to
hospital within 60 minutes once recalled. One out of 70
participants developed contact dermatitis at electrode site (found
after delivery once the electrodes were removed). This resolved
after local steroid ointment was applied for 1 week.
ii) Women’s views
Fifty-one completed diaries were returned, with a median of 6
entries per diary (range 1 to 10). Most women reported that they
coped ‘well’ (n=19) or ‘very well’ (n=29) at home. Direct
quotations are used to illustrate findings.
Comments indicated that the freedom to mobilise and familiar
surroundings influenced their ability to cope with the irregular
contractions.
‘‘Having irregular contractions. Can walk around house, have a drink, food,
lie in bed etc’’ [Participant Diary 33]
Women who coped ‘less well’ (n=3) at home reported issues
with device error (battery failure or signal loss), or anxiety from not
receiving health professional feedback on progress of labour
initiation.
‘‘Coping with the fact that I’m at home but feeling anxious that in eleven
hours nothing has happened and I don’t know if I’m any closer’’ [Participant
Diary 38]
The majority of women reported feeling ‘comfortable’ (n=26),
or very comfortable (n=20) wearing the device, although a few
were initially cautious about disturbing the pads/electrodes.
Satisfaction ratings indicated that the majority of women were
‘satisfied’ (n=21), or ‘very satisfied’ (n=25) that they and their
babies were being adequately monitored at home. Additional
comments indicated that women’s level of satisfaction was
influenced by contact with the hospital; satisfaction levels
increased following telephone contact from the hospital.
‘‘Received a phone call so know that I was being monitored’’ [Participant
Diary 22]
Location preferences expressed at each diary entry point
demonstrated that women would rather be at home (n=47) than
inhospital(n=4).Fewwomen(n=8)reportedexperiencinganyside
effects; minor discomfort from the pesssary (n=4), nausea (n=2),
dizziness (n=1) and headaches (n=1) were highlighted. Twenty two
women expressed feeling concerned at specific time points, usually
when they felt they were no longer able to cope with contractions
and labour pains, or when issues developed with the device.
‘‘Unsure if anything is working. Lots of backache – unsure if its
contractions’’ [Participant Diary 12]
Over 100 positive comments were made about monitoring at
home. Freedom and comfort associated with being in their own
surroundings and being able to sleep in their own beds increased
their ability to relax. Women also appreciated the family support
available to them at home.
‘‘The home monitoring did allow a lot more freedom and I believe that
helped me to remain calm and ultimately helped with a straight forward
labour….I also felt mobile and non-restricted whilst I was wearing the device’’
[Participant Diary 42]
Table 2. Outcome of home monitoring.
Total number of women recruited 104
Number of women withdrawn 34
Number of women monitored at home 70
Successful home monitoring 62 (89%)
,5 hours 11 (18%)
5–10 hours 18 (29%)
.10 hours 33 (53%)
Total monitoring time at home per woman
a 10 h 35 min (1 h 55 min–22 h 4 min)
Monitoring success rate per woman
b 86% (10.5)
Unsuccessful signal transmission at home 8 (11%)
Total monitoring time in hours (median, range) 2 h 7 min (1 h 45 min –12 h)
aMedian (range).
bOverall monitoring success rate - mean (SD).
doi:10.1371/journal.pone.0028129.t002
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at home, although some comments (n=34) were made revealing
women’s occasional worries, such as ‘Am I being monitored?’; ‘Is
everything OK?’ and the lack of direct feedback.
Discussion
A combination of labour induction with slow release retrievable
dinoprostone pessary with a portable home monitoring system
seems a feasible alternative to in-patient induction for selected
patients. There was a high acceptance rate of the overall package.
Perceived benefits of being at home included freedom, mobility,
privacy and comfort of home environment. Having family support
was also beneficial. These findings resonate with existing literature
[1]. Having contacts with health professionals, albeit by telephone,
was welcomed; those who had less contacts reported more anxiety.
The device was considered comfortable and non-restrictive;
however, technical difficulties with monitoring increased the
feelings of anxiety.
Technical difficulties with transmission were mainly associated
with the online server failure i.e. a crash of the server’s hard drive
needed to receive and store FHR data. Inability to telemetrically
monitor the FHR traces in these cases necessitated recall of
women to the hospital.
In the pilot phases skin needed to be exfoliated with medical
sand paper so the electrodes could pass the impedance test. In the
main study this was only done in women who had used
moisturizing gels/lotions on the abdomen; there was no need to
prepare the skin vigorously in the rest of the women. Therefore, in
its current format, this protocol may be suitable for units who have
the resources to train dedicated staff to provide this service. The
process of electrode applications and mobile technology set up
would have to be less challenging for routine use by busy
clinicians.
Clearly, this study was not large enough to address the issue of
safety of outpatient induction with prostaglandins. There are
clinicians who will never approve of this concept claiming that the
risk of hyperstimulation and possible fetal distress is simply too
great. Our dinporostone associated hyperstimulation rate experi-
enced during home monitoring (3.2%) was consistent with the
meta-analyses by Austin et al. [12] and Kelly et al. [13] reporting
the rates of 6.3% and 7.5%, respectively. In addition, we had two
cases of unexplained, persistent FHR abnormalities. Given that
both babies were born in excellent condition, it is possible that
these changes would have resolved spontaneously.
Ideally, a randomised controlled trial would have to be carried
to confirm that outpatient induction with (or without) continuous
fetal monitoring is as safe as hospital induction. Women need to be
able to return to hospital quite quickly i.e. easy access to transport
is essential. Assuming that the induction agent would be the same
in both settings (e.g. slow release dinoprostone), the expected
incidence of clinically relevant adverse neonatal outcome should
not exceed 1%. If one assumes that an additional risk of adverse
outcome from outpatient induction of around 0.2% (1 in 500
home inductions) would be totally unacceptable, nearly 90,000
women would have to be randomised. Such a study would be
needed to exclude the possibility that the risk of outpatient
induction is not 20% greater compared with hospital induction
(1.2% vs. 1%). Less satisfactory, but more practical alternative is to
encourage units who practice outpatient induction to keep
reporting not only successes, but also failures and any adverse
outcomes in an unbiased fashion.
Our pilot study confirms that the use of telemetric trans-
abdominal fECG monitoring device in ambulatory women
undergoing labour induction is feasible and acceptable to women,
resulting in high level of satisfaction with the received care. The
quality of remote signal allowed clinical decision making in real
time in all women. The trade-off between women’s choice, safety
issues and cost-effectiveness will be the main issue once the
technology becomes sufficiently robust and even more user
friendly.
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